Palvella Therapeutics raises $3M to advance rare disease drug

By WebmasterApril 15, 2019November 1st, 2024No Comments

Palvella Therapeutics raises $3M to advance rare disease drug

Previous PostRelmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Next PostIView Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID)